ABSTRACT
Many actions of estradiol (E2), the principal physiological estrogen in vertebrates, are mediated by estrogen receptor-α (ERα) and ERß. An important physiological feature of vertebrate ERs is their promiscuous response to several physiological steroids, including estradiol (E2), Δ5-androstenediol, 5α-androstanediol, and 27-hydroxycholesterol. A novel structural characteristic of Δ5-androstenediol, 5α-androstanediol, and 27-hydroxycholesterol is the presence of a C19 methyl group, which precludes the presence of an aromatic A ring with a C3 phenolic group that is a defining property of E2. The structural diversity of these estrogens can explain the response of the ER to synthetic chemicals such as bisphenol A and DDT, which disrupt estrogen physiology in vertebrates, and the estrogenic activity of a variety of plant-derived chemicals such as genistein, coumestrol, and resveratrol. Diversity in the A ring of physiological estrogens also expands potential structures of industrial chemicals that can act as endocrine disruptors. Compared to E2, synthesis of 27-hydroxycholesterol and Δ5-androstenediol is simpler, leading us, based on parsimony, to propose that one or both of these steroids or a related metabolite was a physiological estrogen early in the evolution of the ER, with E2 assuming this role later as the canonical estrogen. In addition to the well-studied role of the ER in reproductive physiology, the ER also is an important transcription factor in non-reproductive tissues such as the cardiovascular system, kidney, bone, and brain. Some of these ER actions in non-reproductive tissues appeared early in vertebrate evolution, long before the emergence of mammals.
Subject(s)
Endocrine Disruptors/metabolism , Estradiol/metabolism , Estrogens/metabolism , Phytochemicals/metabolism , Receptors, Estrogen/genetics , Receptors, Estrogen/metabolism , Androstenediol/metabolism , Animals , Benzhydryl Compounds/toxicity , DDT/toxicity , Humans , Hydroxycholesterols/metabolism , Lancelets , Phenols/toxicityABSTRACT
BACKGROUND: The specific involvement of the sex steroids in the growth of the prostatic tissue remains unclear. Sex steroid concentrations in plasma and in fresh surgical samples of benign central prostate were correlated to prostate volume. METHODS: Monocentric prospective study performed between September 2014 and January 2017. Age, obesity parameters, and both serum and intraprostatic concentrations of sex steroids were collected complying with the latest Endocrine Society guidelines and the steroids assessed by GC/MS. Statistical calculations were adjusted for age and body mass index (BMI). RESULTS: Thirty-two patients, equally divided between normal- and high-volume prostate groups, were included in the analysis. High-volume prostate patients were older, heavier and had higher BMI. Comparison adjusted for age and BMI showed higher DHT concentrations in high-volume prostate. Both normal- and high-volume prostate tissues concentrate sex steroids in a similar way. Comparison of enzymatic activity surrogate marker ratios within tissue highlighted similar TT/E1 and TT/E2 ratios, and higher DHT/E1 ratio and lower DHT/PSA ratio in the high-volume prostates. CONCLUSIONS: STERPROSER trial provides evidence for higher DHT concentration in highvolume prostates, that could reflect either higher 5-alpha reductase expression or lower expression of downstream metabolizing enzymes such as 3a-hydoxysteroid dehydrogenase.
Subject(s)
Gonadal Steroid Hormones/blood , Gonadal Steroid Hormones/metabolism , Prostate/metabolism , Aged , Androstenediol/blood , Androstenediol/metabolism , Body Mass Index , Dehydroepiandrosterone/blood , Dehydroepiandrosterone/metabolism , Dehydroepiandrosterone Sulfate/blood , Dehydroepiandrosterone Sulfate/metabolism , Dihydrotestosterone/blood , Dihydrotestosterone/metabolism , Estradiol/blood , Estradiol/metabolism , Estrone/blood , Estrone/metabolism , Gas Chromatography-Mass Spectrometry , Humans , Male , Middle Aged , Prospective Studies , Prostatic Hyperplasia/blood , Prostatic Hyperplasia/metabolism , Prostatic Hyperplasia/surgery , Testosterone/blood , Testosterone/metabolism , Urinary Bladder Neoplasms/blood , Urinary Bladder Neoplasms/metabolism , Urinary Bladder Neoplasms/surgeryABSTRACT
Celecoxib has been reported to switch the human SULT2A1-catalyzed sulfonation of 17ß-estradiol (17ß-E2) from the 3- to the 17-position. The effects of celecoxib on the sulfonation of selected steroids catalyzed by human SULT2A1 were assessed through in vitro and in silico studies. Celecoxib inhibited SULT2A1-catalyzed sulfonation of dehydroepiandrosterone (DHEA), androst-5-ene-3ß, 17ß-diol (AD), testosterone (T) and epitestosterone (Epi-T) in a concentration-dependent manner. Low µM concentrations of celecoxib strikingly enhanced the formation of the 17-sulfates of 6-dehydroestradiol (6D-E2), 17ß-dihydroequilenin (17ß-Eqn), 17ß-dihydroequilin (17ß-Eq), and 9-dehydroestradiol (9D-E2) as well as the overall rate of sulfonation. For 6D-E2, 9D-E2 and 17ß-Eqn, celecoxib inhibited 3-sulfonation, however 3-sulfonation of 17ß-Eq was stimulated at celecoxib concentrations below 40 µM. Ligand docking studies in silico suggest that celecoxib binds in the substrate-binding site of SULT2A1 in a manner that prohibits the usual binding of substrates but facilitates, for appropriately shaped substrates, a binding mode that favors 17-sulfonation.
Subject(s)
Cyclooxygenase 2 Inhibitors/pharmacology , Estradiol/metabolism , Pyrazoles/pharmacology , Sulfonamides/pharmacology , Sulfotransferases/metabolism , Androstenediol/metabolism , Binding Sites , Celecoxib , Dehydroepiandrosterone/metabolism , Epitestosterone/metabolism , Equilin/analogs & derivatives , Equilin/metabolism , Humans , Models, Molecular , Molecular Docking Simulation , Pyrazoles/metabolism , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , Sulfonamides/metabolism , Sulfotransferases/genetics , Testosterone/metabolismABSTRACT
Women with polycystic ovary syndrome (PCOS) show high prevalence of endometrial hyperplasia and adenocarcinoma. Endometrial proliferation is increased, evaluated by high levels of Ki67 (cell cycle marker) and low levels of p27 (negative regulator of cell cycle). Nevertheless, endometrial changes in cyclin D1 (positive regulator of cell cycle) in PCOS-women are not described. Androst-5-ene-3ß,17ß-diol (androstenediol), steroid with estrogenic activity present in endometria, could be related to increased endometrial cell proliferation. The objective of this study was to determine protein content of cyclin D1 and androstenediol levels in endometria from PCOS and control-women and to evaluate the possible mechanism favoring cell proliferation associated with hormonal characteristics of patients. Therefore, cyclin D1 protein content in PCOS-women and control-endometrial tissue were assessed by western blot and immunohistochemistry. The androstenediol levels were evaluated by ELISA. To further analyze the effect of steroids (androstenediol, 17ß-estradiol, testosterone) in cell proliferation, levels of proteins cyclin D1, p27 and Ki67 were evaluated in an in vitro model of stromal endometrial cells T-HESC and St-T1b. An increase in cyclin D1 and androstenediol was observed in tissues from PCOS-women relative to control group (p<0.05). In the in vitro model, androstenediol exerted increase in cyclin D1 (p<0.05) and a decrease in p27 protein level (p<0.05), while Ki67 in St-T1b cells increased under this stimulus (p<0.05). Testosterone produces opposite effects in the levels of the above markers (p<0.05). Therefore, the hormonal imbalance associated with this syndrome could alter endometrial tissue homeostasis, promoting cell proliferation. Androstenediol is a molecule that could be involved by stimulating proliferation, whereas testosterone elicits a role of cell cycle repressor.
Subject(s)
Androstenediol/metabolism , Cell Proliferation/drug effects , Polycystic Ovary Syndrome/metabolism , Adult , Androstenedione/metabolism , Cyclin D1/metabolism , Endometrium/drug effects , Endometrium/metabolism , Endometrium/pathology , Female , Humans , Polycystic Ovary Syndrome/pathology , Progesterone/metabolism , Proliferating Cell Nuclear Antigen/metabolism , Testosterone/metabolismABSTRACT
Androst-5-ene-3ß,17ß-diol (ADIOL) and 5α-androstane-3ß,17ß-diol (3ß-DIOL), metabolites of dehydroepiandrosterone (DHEA) and dihydrotestosterone (DHT), respectively, are known to possess estrogenic properties. To better understand their hormonal action and roles in the proliferation of breast cancer (BC) cells, we studied their binding to sex-hormone receptors in estrogen receptor (ER)-positive (ZR-75-1 and T-47D) and ER-negative (MDA-MB-231) human BC cells. The results demonstrated that estradiol (E2), ADIOL and 3ß-DIOL stimulated the proliferation of ZR-75-1 and T-47D cells, but had no effect on ER-negative cells. In the presence of estradiol, ADIOL and 3ß-DIOL inhibited the estrogen-stimulated BC cell growth. This inhibition was counteracted by anti-androgens, which were unable to affect the ADIOL and 3ß-DIOL stimulatory effects in E2-free medium. On the other hand, in the presence of tamoxifen, ADIOL and 3ß-DIOL showed an additional anti-proliferative activity on hormone-sensitive BC cells compared with tamoxifen treatment alone. These results are similar to previous reports obtained using MCF-7 cells, which confirmed that ADIOL and 3ß-DIOL stimulated estrogen-dependent BC cell growth via ERs, but inhibited growth via androgen receptors (ARs). Several steroids bind to both ER and AR in a different preference and degree, i.e. E2>estrone (E1)>ADIOL>3ß-DIOL>testosterone (T)>DHT for ER and DHT>T>3ß-DIOL>ADIOL>E1>E2 for AR. The relative binding affinities of ADIOL, 3ß-DIOL, and E2 corresponded well to their respective potential in stimulating cell proliferation of ZR-75-1 and T-47D cells in our results. The intrinsic relationship between cell proliferation effects and binding affinities for receptors of several steroids was revealed here by a combined binding and cell study. This article is part of a Special Issue entitled 'Synthesis and biological testing of steroid derivatives as inhibitors'.
Subject(s)
Androstane-3,17-diol/metabolism , Androstenediol/metabolism , Receptors, Androgen/metabolism , Receptors, Estrogen/metabolism , Cell Line, Tumor , Humans , Protein BindingABSTRACT
Estradiol (E2) is the principal physiological estrogen in mammals. E2 and its active metabolites, estrone and estriol have a characteristic phenolic A ring, unlike progesterone, testosterone, cortisol and aldosterone, which have an A ring containing a C3-ketone, a Δ(4) bond and a C19 methyl group. Crystal structures of E2 in the estrogen receptor (ER) confirm the importance of the A ring in stabilizing E2 in the ER. However, other steroids, including Δ(5)-androstenediol, 5α-androstanediol and 27-hydroxycholesterol, which have a saturated A ring containing a 3ß-hydroxyl and a C19 methyl group, also mediate physiological responses through binding to estrogen receptor-α (ERα) and ERß. Moreover, selective estrogen response modulators (SERMs) with diverse structures also regulate transcription of ERα and ERß. Our understanding of the physiological responses mediated by these "alternative" estrogens is in its infancy. Further studies of the role of these steroids and SERMs in regulating responses mediated by ERα and ERß a variety of tissues, during different stages of development, are likely to uncover additional estrogenic activities.
Subject(s)
Estrogen Receptor alpha/genetics , Estrogen Receptor beta/genetics , Selective Estrogen Receptor Modulators/pharmacology , Androstenediol/chemistry , Androstenediol/metabolism , Androstenediol/pharmacology , Animals , Bone and Bones/drug effects , Bone and Bones/physiology , Brain/drug effects , Brain/physiology , Estradiol/chemistry , Estradiol/metabolism , Estradiol/pharmacology , Estriol/chemistry , Estriol/metabolism , Estriol/pharmacology , Estrogen Receptor alpha/metabolism , Estrogen Receptor beta/metabolism , Estrone/chemistry , Estrone/metabolism , Estrone/pharmacology , Gene Expression Regulation/drug effects , Humans , Hydroxycholesterols/chemistry , Hydroxycholesterols/metabolism , Hydroxycholesterols/pharmacology , Male , Prostate/drug effects , Prostate/physiology , Selective Estrogen Receptor Modulators/chemistry , Selective Estrogen Receptor Modulators/metabolism , Signal Transduction/drug effects , Structure-Activity Relationship , Transcription, Genetic/drug effectsABSTRACT
We investigated the capacity for vitamin D receptor (VDR) to modulate the expression of CYP3A4 and other genes that may facilitate the oxidative inactivation of androgens such as testosterone and androstanediol within prostate cells. We report that exposure to the active hormonal form of vitamin D markedly increased gene expression of CYP3A4 and CYP3A5 and ultimately achieved levels of intracellular CYP3A enzyme activity within LNCaP prostate cancer cells that were comparable to that observed for Caco2 cells, an established model of CYP3A induction, and resulted in the increased turnover of testosterone to its inactive 6ß-OH metabolite. We demonstrate that VDR directs CYP3A4 and CYP3A5 expression through binding to distinct regulatory motifs located within the 5' promoter regions of both genes. The current data highlight the potential application of VDR-based treatment regimes as a means to limit the bioavailability of growth-promoting androgens within the tumor microenvironment.
Subject(s)
Androstenediol/metabolism , Calcitriol/pharmacology , Cytochrome P-450 CYP3A/genetics , Cytochrome P-450 CYP4A/genetics , Prostatic Neoplasms/genetics , Receptors, Calcitriol/genetics , Testosterone/metabolism , Caco-2 Cells , Calcitriol/metabolism , Cell Line, Tumor , Cytochrome P-450 CYP3A/metabolism , Cytochrome P-450 CYP4A/metabolism , Gene Expression Regulation/drug effects , Humans , Ligands , Male , Promoter Regions, Genetic , Prostate/drug effects , Prostate/enzymology , Prostate/pathology , Prostatic Neoplasms/enzymology , Prostatic Neoplasms/pathology , Receptors, Calcitriol/metabolism , TransfectionABSTRACT
Recently, binding of 5-androsten-3ß,17ß-diol (Δ(5)-androstenediol) to human estrogen receptor-beta (ERß) was found to repress microglia-mediated inflammation, which is associated with various neurodegenerative diseases, such as multiple sclerosis. In contrast, binding of estradiol to ERß resulted in little or no repression of microglia-mediated inflammation. Binding of Δ(5)-androstenediol to ERß, as well as to ERα, is unexpected because unlike estradiol, Δ(5)-androstenediol has a saturated A ring and a C19 methyl group. To begin to elucidate the interaction of Δ(5)-androstenediol with both ERs, we constructed 3D models of Δ(5)-androstenediol with human ERα and ERß for comparison with the crystal structures of estradiol in ERα and ERß. Conformational flexibility in human ERα and ERß accommodates the C19 methyl on Δ(5)-androstenediol. This conformational flexibility may be relevant for binding of other Δ(5)-steroids with C19 methyl substituents, such as 25-hydroxycholesterol and 27-hydroxycholesterol, to ERs.
Subject(s)
Androstenediol/metabolism , Estrogen Receptor alpha/chemistry , Estrogen Receptor alpha/metabolism , Estrogen Receptor beta/chemistry , Estrogen Receptor beta/metabolism , Molecular Docking Simulation , Amino Acid Sequence , Estradiol/metabolism , Humans , Molecular Sequence Data , Protein Binding , Protein Conformation , Protein StabilitySubject(s)
Antineoplastic Agents/therapeutic use , Etiocholanolone/analogs & derivatives , Prostatic Neoplasms/drug therapy , Prostatic Neoplasms/metabolism , Testosterone/metabolism , 3-Hydroxysteroid Dehydrogenases/metabolism , Abiraterone Acetate , Androstadienes/therapeutic use , Androstenediol/metabolism , Dehydroepiandrosterone/metabolism , Etiocholanolone/metabolism , Humans , Male , Orchiectomy , Receptors, Androgen/metabolism , Testosterone/bloodABSTRACT
BACKGROUND: To evaluate the metabolic changes in urinary steroids in pre- and post-menopausal women and men with papillary thyroid carcinoma (PTC). METHODS: Quantitative steroid profiling combined with gas chromatography-mass spectrometry was used to measure the urinary concentrations of 84 steroids in both pre- (n = 21, age: 36.95 ± 7.19 yr) and post-menopausal female (n = 19, age: 52.79 ± 7.66 yr), and male (n = 16, age: 41.88 ± 8.48 yr) patients with PTC. After comparing the quantitative data of the patients with their corresponding controls (pre-menopause women: n = 24, age: 33.21 ± 10.48 yr, post-menopause women: n = 16, age: 49.67 ± 8.94 yr, male: n = 20, age: 42.75 ± 4.22 yr), the levels of steroids in the patients were normalized to the mean concentration of the controls to exclude gender and menopausal variations. RESULTS: Many urinary steroids were up-regulated in all PTC patients compared to the controls. Among them, the levels of three active androgens, androstenedione, androstenediol and 16α-hydroxy DHEA, were significantly higher in the pre-menopausal women and men with PTC. The corticoid levels were increased slightly in the PTC men, while progestins were not altered in the post-menopausal PTC women. Estrogens were up-regulated in all PTC patients but 2-hydroxyestrone and 2-hydroxy-17ß-estradiol were remarkably changed in both pre-menopausal women and men with PTC. For both menopausal and gender differences, the 2-hydroxylation, 4-hydroxylation, 2-methoxylation, and 4-methoxylation of estrogens and 16α-hydroxylation of DHEA were differentiated between pre- and post-menopausal PTC women (P < 0.001). In particular, the metabolic ratio of 2-hydroxyestrone to 2-hydroxy-17ß-estradiol, which could reveal the enzyme activity of 17ß-hydroxysteroid dehydrogenase, showed gender differences in PTC patients (P < 1 × 10-7). CONCLUSIONS: These results are expected be helpful for better understanding the pathogenic differences in PTC according to gender and menopausal conditions.
Subject(s)
Carcinoma, Papillary/urine , Postmenopause/urine , Premenopause/urine , Steroids/urine , Thyroid Neoplasms/urine , Adult , Androstenediol/metabolism , Androstenediol/urine , Androstenedione/metabolism , Androstenedione/urine , Carcinoma, Papillary/metabolism , Dehydroepiandrosterone/analogs & derivatives , Dehydroepiandrosterone/metabolism , Dehydroepiandrosterone/urine , Estradiol/analogs & derivatives , Estradiol/metabolism , Estradiol/urine , Estrogens/metabolism , Estrogens/urine , Female , Gas Chromatography-Mass Spectrometry , Humans , Hydroxyestrones/metabolism , Hydroxyestrones/urine , Male , Middle Aged , Multivariate Analysis , Postmenopause/metabolism , Premenopause/metabolism , Sex Factors , Steroids/metabolism , Thyroid Neoplasms/metabolismABSTRACT
The course of transformation of DHEA, androstenediol and epiandrosterone in Mortierella isabellina AM212 culture was investigated. The mentioned substrates underwent effective hydroxylation; 5-ene substrates--DHEA and androstenediol--were transformed into a mixture of 7α- and 7ß- allyl alcohols, while epiandrosterone was converted into 7α- (mainly), 11α- and 9α- monohydroxy derivatives. Ketoconazole and cycloheximide inhibition studies suggest the presence of constitutive and substrate-induced hydroxylases in M. isabellina. On the basis of time course analysis of the hydroxylation of DHEA and androstenediol, the oxidation of allyl C(7)-H(α) and C(7)-H(ß) bonds by the same enzyme is a reasonable assumption.
Subject(s)
Androstenediol/chemistry , Androsterone/chemistry , Dehydroepiandrosterone/chemistry , Mixed Function Oxygenases/chemistry , Mortierella/enzymology , Androstenediol/metabolism , Androstenediol/pharmacology , Androsterone/metabolism , Androsterone/pharmacology , Binding Sites , Catalysis , Crystallography, X-Ray , Cycloheximide/antagonists & inhibitors , Dehydroepiandrosterone/metabolism , Hydroxylation , Ketoconazole/antagonists & inhibitors , Mixed Function Oxygenases/metabolism , Molecular Structure , Mortierella/chemistryABSTRACT
Estrogens play an important role in the pathobiology of breast cancer. In postmenopausal women, peripheral synthesis of estrogens from adrenal/ovarian androgens, dehydroepiandrosterone (DHEA) or androstenedione (Adione), by estrogen-metabolizing enzymes is important. Besides estrone (E1) and estradiol (E2), androgen metabolites, such as androstene-3ß, 17ß-diol (Aenediol) or 5α-androstane-3ß, 17ß-diol (Aanediol), are known to have estrogenic functions, although they have been studied much less in breast cancer. To precisely elucidate steroid metabolism in breast cancer patients and to identify the pathobiological role of estrogenic androgen metabolites, concentrations of DHEA, Adione, Aenediol, Aanediol, E1, and E2 in pairs of serum and tumor tissue from patients with primary breast cancer were measured by liquid chromatography-tandem mass spectrometry. Cell proliferation assays using Aenediol were performed for four breast cancer cell lines. Serous E2 concentration was extremely low in postmenopausal women; however, a marked increase in tumor tissue was observed in hormone receptor-positive cases. E1 concentration, in contrast, was sustained at a higher level, even in postmenopausal serum, and did not increase in tumor tissue irrespective of the hormone receptor status. Dehydroepiandrosterone was most abundant in all samples, and exhibited a similar pattern as Adione and Aenediol. 5α-Androstane-3ß, 17ß-diol was undetectable in most samples. Androstene-3ß, 17ß-diol proliferated estrogen receptor-apositive breast cancer cells in the absence of E2. The intratumoral increase of E2, but not E1, in hormone receptor-positive postmenopausal breast cancer tissue, as well as the proliferative role of Aenediol, was elucidated.
Subject(s)
Androstenediol/metabolism , Breast Neoplasms/metabolism , Gonadal Steroid Hormones/blood , Adult , Androstenedione/biosynthesis , Androstenedione/blood , Breast Neoplasms/blood , Breast Neoplasms/pathology , Cell Line, Tumor , Cell Proliferation , Dehydroepiandrosterone/biosynthesis , Dehydroepiandrosterone/blood , Estradiol/biosynthesis , Estradiol/blood , Estrogen Receptor alpha/metabolism , Estrone/biosynthesis , Estrone/blood , Female , Humans , Middle Aged , Postmenopause , PremenopauseABSTRACT
High-affinity binding of dihydrotestosterone (DHT) to the androgen receptor (AR) initiates androgen-dependent gene activation, required for normal male sex development in utero, and contributes to prostate cancer development and progression in men. Under normal physiologic conditions, DHT is synthesized predominantly by 5α-reduction of testosterone, the major circulating androgen produced by the testis. During androgen deprivation therapy, intratumoral androgen production is sufficient for AR activation and prostate cancer growth, even though circulating testicular androgen levels are low. Recent studies indicate that the metabolism of 5α-androstane-3α, 17ß-diol by 17ß-hydroxysteroid dehydrogenase 6 in benign prostate and prostate cancer cells is a major biosynthetic pathway for intratumoral synthesis of DHT, which binds AR and initiates transactivation to promote prostate cancer growth during androgen deprivation therapy. Drugs that target the so-called backdoor pathway of DHT synthesis provide an opportunity to enhance clinical response to luteinizing-hormone-releasing hormone (LHRH) agonists or antagonists, AR antagonists, and inhibitors of 5α-reductase enzymes (finasteride or dutasteride), and other steroid metabolism enzyme inhibitors (ketoconazole or the recently available abiraterone acetate).
Subject(s)
Androstenediol/metabolism , Dihydrotestosterone/metabolism , Prostatic Neoplasms/enzymology , Cholestenone 5 alpha-Reductase/antagonists & inhibitors , Cholestenone 5 alpha-Reductase/metabolism , Enzyme Inhibitors/pharmacology , Enzyme Inhibitors/therapeutic use , Humans , Male , Molecular Targeted Therapy , Prostatic Neoplasms/drug therapy , Prostatic Neoplasms/genetics , Signal Transduction/drug effects , Steroid 17-alpha-Hydroxylase/antagonists & inhibitors , Steroid 17-alpha-Hydroxylase/genetics , Steroid 17-alpha-Hydroxylase/metabolismABSTRACT
Microglia and astrocytes play essential roles in the maintenance of homeostasis within the central nervous system, but mechanisms that control the magnitude and duration of responses to infection and injury remain poorly understood. Here, we provide evidence that 5-androsten-3ß,17ß-diol (ADIOL) functions as a selective modulator of estrogen receptor (ER)ß to suppress inflammatory responses of microglia and astrocytes. ADIOL and a subset of synthetic ERß-specific ligands, but not 17ß-estradiol, mediate recruitment of CtBP corepressor complexes to AP-1-dependent promoters, thereby repressing genes that amplify inflammatory responses and activate Th17 T cells. Reduction of ADIOL or ERß expression results in exaggerated inflammatory responses to TLR4 agonists. Conversely, the administration of ADIOL or synthetic ERß-specific ligands that promote CtBP recruitment prevents experimental autoimmune encephalomyelitis in an ERß-dependent manner. These findings provide evidence for an ADIOL/ERß/CtBP-transrepression pathway that regulates inflammatory responses in microglia and can be targeted by selective ERß modulators.
Subject(s)
Encephalomyelitis, Autoimmune, Experimental/metabolism , Estrogen Receptor beta/metabolism , Inflammation/metabolism , Microglia/metabolism , Signal Transduction , 17-Hydroxysteroid Dehydrogenases/metabolism , Alcohol Oxidoreductases/metabolism , Androstenediol/metabolism , Animals , Astrocytes/metabolism , Cells, Cultured , DNA-Binding Proteins/metabolism , Encephalomyelitis, Autoimmune, Experimental/prevention & control , Humans , Mice , Mice, Inbred C57BL , Neurodegenerative Diseases/metabolism , Proto-Oncogene Proteins c-fos/metabolismABSTRACT
The potent anti-inflammatory activity of exogenous dehydroepiandrosterone (DHEA) in rodents has not translated to humans. This disparity in pharmacological effects has been attributed to factors such as differences in expression and function of molecular targets and differential metabolism. Hepatocytes from rats, dogs, monkeys, and humans were used to measure species-specific metabolism of a related compound, androst-5-ene-3ß,17ß-diol (5-AED) using reversed-phase radio-HPLC, to explore the metabolic contribution to this interspecies disparity. We found that rat hepatocytes transformed 5-AED predominantly into an array of highly oxidized metabolites. Canine metabolites overlapped with rat, but contained a greater abundance of less hydrophilic species. Monkey and human metabolites were strikingly less hydrophilic, dominated by 5-AED and DHEA conjugates. From the accumulating evidence indicating that the DHEA anti-inflammatory activity may actually reside in its more highly oxidized metabolites, we advance a hypothesis that the virtual absence of these metabolites in humans is central to the failure of exogenous DHEA to produce a potent pharmacological effect in clinical investigations. Accordingly, emulation of its anti-inflammatory activity in humans will require administration of an active native metabolite or a synthetic pharmaceutical derivative.
Subject(s)
Androstenediol/metabolism , Haplorhini , Animals , Anti-Inflammatory Agents/metabolism , Anti-Inflammatory Agents/pharmacology , Dehydroepiandrosterone/metabolism , Dehydroepiandrosterone/pharmacology , Dogs , Hepatocytes/drug effects , Hepatocytes/metabolism , Humans , Rats , Species SpecificityABSTRACT
The mechanism accounting for the development of castration-resistant prostate cancer (CRPC) remains unclear. Studies in CRPC tissues suggest that, after androgen deprivation therapy (ADT), the adrenal androgens may be an important source of testosterone (T) and 5-alpha dihydrotestosterone (DHT) in CRPC tissues. To clarify the role of adrenal androgens in the prostatic tissues (prostatic tissue adrenal androgens) during ADT, we developed a high sensitive and specific quantification method for the levels of androgens in prostatic tissue using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Human prostatic tissues were purified using mixed-mode reversed-phase, strong anion exchange Oasis cartridges (Oasis MAX). Analysis of steroids was performed using LC-MS/MS after picolinic acid derivatization. The validation tests showed that our method of quantitative analysis was precise and sensitive enough for the quantification of dehydroepiandrosterone (DHEA), androstenedione, androstenediol, T, and DHT in the prostatic tissue. The levels of adrenal androgens in prostate cancer tissues after ADT were similar to those in untreated PCa. Especially, DHEA was the most existing androgen precursor in PCa tissues after ADT. The levels of DHEA were high in PCa tissues, irrespective of ADT. We assumed that DHEA played a significant role in the synthesis of T and DHT in PCa tissues after ADT.
Subject(s)
Adrenal Glands/metabolism , Androgens/analysis , Prostate/metabolism , Prostatic Neoplasms/metabolism , Androgens/metabolism , Androstenediol/analysis , Androstenediol/metabolism , Androstenedione/analysis , Androstenedione/metabolism , Castration/methods , Chromatography, Liquid , Dehydroepiandrosterone/analysis , Dehydroepiandrosterone/metabolism , Dihydrotestosterone/analysis , Dihydrotestosterone/metabolism , Humans , Male , Prostate/pathology , Prostate/surgery , Prostatic Neoplasms/surgery , Prostatic Neoplasms/therapyABSTRACT
The changes in endometrial homeostasis found in women with polycystic ovarian syndrome (PCOS) could be associated with alterations in the intracrine metabolism of steroid hormones. The uptake of dehydroepiandrosterone-sulphate (DHEA-S), precursor of the intracrine pathway, is achieved by transporters, such as organic anion transporter polypeptides (OATPs), and molecules with oestrogenic activity, such as androst-5-ene-3beta,17beta-diol (androstenediol), can be generated. We aimed to determine androstenediol generation and the expression of OATPs in human endometria throughout the menstrual cycle and in endometria from PCOS women. Endometrial samples were obtained from control women in the proliferative phase (control endometria (CEp), n=7), secretory phase (CEs, n=7), and from PCOS patients (PCOSEp, n=7). The mRNA levels of OATP-B, OATP-D and OATP-E were measured by reverse transcriptase polymerase chain reaction (RT-PCR) and protein levels of OATP-E by immunofluorescence; 3beta-hydroxysteroid dehydrogenase (HSD) by immunohistochemistry/Western blot; the metabolism of DHEA to androstenediol was evaluated by thin layer chromatography-high-performance liquid chromatography (TLC-HPLC). Lower levels of OATP-E transcript were obtained in PCOSEp (p<0.05) compared with CEp, while OATP-E protein levels (p<0.05) and DHEA conversion to androstenediol (p<0.01) were higher in PCOSEp. Lower 3beta-(hydroxysteroid dehydrogenase) HSD protein levels were found in PCOSEp (p<0.05) (Western blot, immunohistochemistry). These results reveal a higher capacity of the endometria from PCOS women to metabolise DHEA to androstenediol, which, coupled with the high oestrogen sensitivity previously found in these endometria, may account for the increase in cell proliferation in PCOSEp already reported.
Subject(s)
Androstenediol/metabolism , Dehydroepiandrosterone/metabolism , Endometrium/metabolism , Polycystic Ovary Syndrome/metabolism , 3-Hydroxysteroid Dehydrogenases/metabolism , Adult , Female , Humans , Menstrual Cycle/metabolism , Organic Anion Transporters/genetics , Polycystic Ovary Syndrome/genetics , Polycystic Ovary Syndrome/physiopathology , Polycystic Ovary Syndrome/therapy , RNA, Messenger/genetics , RNA, Messenger/metabolism , Sulfuric Acids/metabolismABSTRACT
This report illustrates that the beta-androstenes are indeed able to upregulate the host immune response to a level that enables the host to resist lethal infection by viruses or bacteria. These agents consist of a subgroup of steroids, which also mediates a rapid recovery of hematopoietic precursor cells after whole-body lethal radiation injury. In vivo, the androstenes increase the levels of the Th1 cytokines such as IL-2, IL-3, and IFN. Similar to hydrocortisone, they suppress inflammation, but without immune suppression, and have a role in the maintenance of the Th1/Th2 balance and immune homeostasis.
Subject(s)
Androstenediol/metabolism , Bacterial Infections/immunology , Dehydroepiandrosterone/physiology , Virus Diseases/immunology , Androstenols/pharmacology , Androstenols/therapeutic use , Animals , Coxsackievirus Infections/drug therapy , Coxsackievirus Infections/immunology , Dehydroepiandrosterone/pharmacology , Dehydroepiandrosterone/therapeutic use , Drug Evaluation, Preclinical , Enterococcus faecalis/drug effects , Enterovirus B, Human/drug effects , Enterovirus B, Human/physiology , Gram-Positive Bacterial Infections/drug therapy , Gram-Positive Bacterial Infections/immunology , Herpes Simplex/drug therapy , Herpes Simplex/immunology , Herpesvirus 2, Human/drug effects , Herpesvirus 2, Human/physiology , Homeostasis , Humans , Immunity, Innate , Interferons/metabolism , Interleukin-2/metabolism , Interleukin-3/metabolism , Mice , Mice, Hairless , Mice, Inbred C57BL , Th1 Cells/metabolism , Virus Replication/drug effectsABSTRACT
Helix pomatia (Hp) juice is a common enzymatic preparation for deconjugation of urinary steroids. It has been used in many published studies on urinary testosterone (T) in chimpanzees and bonobos, although the ability of Hp juice to convert other urinary steroids into T has been reported for human urine. We developed a protocol for determination of reliable T levels in primate urine using liquid chromatography-mass spectrometry. T levels were determined in a set of human, bonobo and chimpanzee urine samples (A) by measurement of intact testosterone glucuronide (TG) and testosterone sulfate (TS), (B) after hydrolysis/solvolysis with beta-glucuronidase from Hp and (C) from Escherichia coli. When samples were hydrolyzed with Hp juice, results were not correlated with the direct assay of TG and TS, and determined T concentrations were considerably higher. By contrast, hydrolysis with E. coli beta-glucuronidase yielded a good agreement of T concentrations. We demonstrated the ability of Hp juice to convert androst-5-ene-3beta, 17beta-diol (A(5)diol) into T using commercial standards and within the urine of all three species. As A(5)diol usually is present at higher levels in urine than T, this artifact leads to erroneous results for T concentrations in primate urine. The proportion of T excreted as sulfate (TS) is often neglected as TS can only be cleaved by additional solvolysis. In all three species, we found substantial amounts of TS in the urine of some subjects and a high variance of TS proportion between and within subjects. Therefore the inclusion of solvolysis into the sample preparation seems necessary.
Subject(s)
Clinical Laboratory Techniques , Glucuronidase/metabolism , Hominidae/urine , Pan paniscus/urine , Pan troglodytes/urine , Testosterone/urine , Adult , Androstenediol/metabolism , Animals , Body Fluids/enzymology , Calibration , Clinical Laboratory Techniques/standards , Glucuronidase/chemistry , Humans , Hydrolysis , Male , Snails/chemistry , Snails/metabolism , Solid Phase Extraction/methods , Testosterone/isolation & purification , Testosterone/metabolismABSTRACT
Larval and adult stages of Taenia solium and Taenia crassiceps WFU strain were analyzed by histochemical and biochemical methods to determine the existence of steroid pathways. The presence of the key enzyme 3beta-hydroxisteroid-dehydrogenase (3beta-HSD) was examined in frozen sections of cysticerci obtained from mice and segments of tapeworms obtained from the intestine of hamsters. 3beta-HSD activity was detected by nitroblue-tetrazolium products after incubation with dehydroepiandrosterone, androstendiol, or pregnenolone. Tapeworm tissues exhibited 3beta-HSD activity in the subtegumentary areas of the neck and immature proglottids following incubation with androstendiol, as well as surrounding the testes in mature proglottids. T. solium cysticerci exhibited 3beta-HSD activity in the subtegumentary tissues. The synthesis of steroid hormones involving the activity of 3beta-HSD was studied in cysticerci or tapeworms incubated in the presence of tritiated steroid precursors. The culture media were analyzed by thin layer chromatography and showed synthesis of androstendiol, testosterone, and 17beta-estradiol by cysticerci, androstendiol, and 17beta-estradiol by tapeworms. The results strongly suggest the activity of 3beta-HSD in taeniid parasites that have at least a part of the enzymatic chain required for androgen and estrogen synthesis and that the enzymes are present in the larval stage and from the early strobilar stages to the mature proglottids.